Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

BioCellChallenge Launches the First Universal Delivery System

Published: Thursday, February 21, 2013
Last Updated: Thursday, February 21, 2013
Bookmark and Share
This new technology means thousands of existing antibodies can now be used as research tools, with or without additives.

BioCellChallenge SAS has announced the launch of a new delivery system, ImmunoCellin, which is designed to transport antibodies into live cells even in the presence of additives. The company has recently filed a patent for this pioneering technology.

Without a suitable nanocarrier, antibodies cannot cross the plasmic membrane of live cells unaided and reach their potential intracellular targets.

ImmunoCellin delivers antibodies directly into live cells, without any particular advanced preparation. This system is especially effective in identifying new targets for future therapeutic treatments.

"Until now, cellular biology research projects have made little use of antibody transport into live cells, largely because all the tools are not sufficiently effective to be used without a lot of preparation or re-engineering. However, there is particular benefit in introducing therapeutic antibodies to target the intracellular proteins involved in certain diseases, particularly in certain cancers," explains Dr Meunier, CEO of BioCellChallenge.

ImmunoCellin is a much more potent protein function inhibitor than siRNA (small interfering RNA). Using siRNA to prevent a protein from playing its role in the cell inhibits all the functions of that protein.

With ImmunoCellin, however, monoclonal antibodies can be directed to a single region of the protein to interfere with a single molecular mechanism, meaning that a specific function of the protein can be determined with certainty.

ImmunoCellin is therefore a powerful tool for developing a broader understanding of the inter-protein interactions which form the basis of cell function.

ImmunoCellin is also particularly suitable for use in kinetic studies of intracellular protein localization in response to different stimuli. It can also directly interfere with protein traffic in the cytosol or the nucleus; by targeting a localization signal, for example.

The reagent is very simple to use: a few microlitres of the reagent are mixed with a few micrograms of antibody and this mixture is then added to the cells.

No other preparation is required. The lipid-based formulation encapsulates the antibodies, facilitating their passage through the membrane.

There is no covalent interaction between the transport system and the antibody. Once inside the cell, the system does not retain the antibody, which can then diffuse freely through the cytosol until it reaches its target.

Since no chemical coupling is required, there is no impact on the activity of the antibody. Finally, as this system is not inhibited by the presence of serum, in vivo approaches are also possible.

This new system is aimed particularly at pharmaceutical and biotechnology industry R&D teams working on therapeutic antibodies.

Accordingly, BioCellChallenge is keen to develop partnerships with players in the pharmaceutical and biotechnology industry. The ImmunoCellin system is also particularly relevant to cellular and molecular research biologists worldwide.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Untangling Disease-Related Protein Misfolding
Work advances understanding of genetic forms of thrombosis, emphysema, cirrhosis of the liver, neurodegenerative diseases and inflammation, among others.
Developing a More Precise Seasonal Flu Vaccine
During the 2014-15 flu season, the poor match between the virus used to make the world’s vaccine stocks and the circulating seasonal virus yielded a vaccine that was less than 20 percent effective.
Fighting Cancer with Borrowed Immunity
A new step in cancer immunotherapy: researchers from the Netherlands Cancer Institute and University of Oslo/Oslo University Hospital show that even if one's own immune cells cannot recognize and fight their tumors, someone else's immune cells might.
Loss Of Y Chromosome Increases Risk Of Alzheimer’s
Men with blood cells that do not carry the Y chromosome are at greater risk of being diagnosed with Alzheimer’s disease. This is in addition to an increased risk of death from other causes, including many cancers. These new findings by researchers at Uppsala University could lead to a simple test to identify those at risk of developing Alzheimer’s disease.
Immune Cells Remember Their First Meal
Scientists at the University of Bristol have identified the trigger for immune cells' inflammatory response – a discovery that may pave the way for new treatments for many human diseases.
"Sunscreen" Gene May Guard Against Melanoma
USC-led study reveals that melanoma patients with deficient or mutant copies of the gene are less protected from harmful ultraviolet rays.
Myeloid-Derived Suppressor Cells Play Role in Tumor Growth
Researchers at Baylor College of Medicine have reported a new mechanism that helps cancer cells engage myeloid-derived suppressor cells.
Drug Might Help Treat Sepsis
A DNA enzyme called Top1 plays a key role in turning on genes that cause inflammation in mouse and human cells in response to pathogens. A drug blocking this enzyme rescued mice from lethal inflammatory responses, suggesting a potential treatment for sepsis.
Large-scale HIV Vaccine Trial to Launch in South Africa
NIH-funded study will test safety, efficacy of vaccine regimen.
Immune System Implicated in Gastroschisis
UCSF researchers show that the immune system is implicated in gastroschisis. The findings could lead to improved treatments for the belly birth defect.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!